Pharmaceuticals APAC

APAC Diabetes Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $14.43 Bn Placeholder estimate
Estimate 2025 $15.65 Bn 20.1% of the global market
Projected 2034 $32.34 Bn 106.7% Adds $16.69 Bn over 9 forecast years
CAGR 2025–2034 8.4% Faster than 42% of 183 Pharmaceuticals markets here
Key players 6 +1
  • APAC is 20.1% of the global market.
  • Among regions, the largest is North America at $40.19 Bn.
  • Fastest growing: Africa at 8.9% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$16.69 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Drugs Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $14.43 Bn — —
2025 (base) $15.65 Bn +$1.21 Bn —
2026 (forecast) $16.96 Bn +$1.31 Bn +8.4%
2027 (forecast) $18.39 Bn +$1.42 Bn +17.5%
2028 (forecast) $19.93 Bn +$1.54 Bn +27.4%
2029 (forecast) $21.60 Bn +$1.67 Bn +38.1%
2030 (forecast) $23.42 Bn +$1.81 Bn +49.7%
2031 (forecast) $25.39 Bn +$1.97 Bn +62.2%
2032 (forecast) $27.52 Bn +$2.13 Bn +75.9%
2033 (forecast) $29.83 Bn +$2.31 Bn +90.6%
2034 (forecast) $32.34 Bn +$2.51 Bn +106.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Diabetes Drugs Market Analysis at a glance
Market size, 2025$15.65 Bn placeholder estimate
Forecast, 2034$32.34 Bn placeholder estimate
Growth (CAGR), 2025–20348.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Diabetes Drugs Market Analysis Executive Summary

Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.

Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).

Bar chart: Asia Pacific Diabetes Drugs market size, 2024–2034, placeholder estimates. $14.43 Bn in 2024, $15.65 Bn in 2025 and $32.34 Bn in 2034, 8.4% CAGR.
Asia Pacific Diabetes Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Diabetes Drugs Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.

Competitive Landscape for Diabetes Drugs Market in APAC

The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Drugs Market in APAC

Diabetes Drugs in APAC: rules and payment

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], BPOM (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Drug Administration of Vietnam (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Drug Administration of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.

Patients

Diabetes (ages 20–79), % of people 20–79 (World Bank)
CountryValueYear
Afghanistan11.72024
Australia7.42024
Bangladesh13.22024
China11.92024
Hong Kong8.22024
India10.52024
Indonesia11.32024
Japan8.12024
Malaysia21.12024
Myanmar6.72024
Nepal7.72024
New Zealand6.72024
Pakistan31.42024
Philippines7.52024
Singapore11.42024
South Korea9.62024
Thailand10.22024
Vietnam3.42024
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Drugs market in Asia Pacific?
Placeholder estimate: about $15.65 Bn in 2025, rising to about $32.34 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Drugs market in Asia Pacific growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Drugs market report cover?
The report splits the market by drug class (Insulin, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors and more), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Diabetes Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and Boehringer Ingelheim GmbH.
What is driving the Diabetes Drugs market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on diabetes

See the topic